argenx, through its subsidiary, has officially launched a cash tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share. This filing confirms the commencement of the acquisition process, which will result in Forte becoming a wholly-owned subsidiary of argenx without a stockholder vote.
argenx has formally initiated its tender offer to acquire Forte Biosciences for $77.00 per share in cash. This is a significant corporate event, as it marks the official start of the acquisition process, following the previously announced merger agreement. For Forte Biosciences shareholders, this represents a clear exit at a premium, likely leading to a positive short-term price movement towards the offer price. For argenx, this acquisition expands its portfolio and potentially its market reach, though the immediate market reaction might be neutral as the deal was already announced. The transaction is structured to proceed without a vote from Forte's stockholders, ensuring a streamlined acquisition process. Traders should monitor the tender offer's progress and the closing of the deal, as FBRX shares will likely trade close to the offer price until the acquisition is complete.